Corvus Pharma adds David Moore to board

Corvus Pharmaceuticals, Inc. appointed David Moore to its Board of Directors effective October 2, 2025.

Rhea-AI Filing Summary

Corvus Pharmaceuticals, Inc. appointed David Moore to its Board of Directors effective October 2, 2025. He will serve as a Class III director with a term extending to the 2028 annual meeting of stockholders and will also join the Compensation Committee and the Nominating and Corporate Governance Committee.

Under the company’s non-employee director compensation program, Mr. Moore will receive a $35,000 annual cash retainer for Board service, plus $6,000 annually for serving on the Compensation Committee and $4,000 annually for serving on the Nominating Committee, each earned quarterly and prorated for the current quarter. He will also receive an initial stock option to purchase 30,000 shares of common stock under the 2016 Equity Incentive Award Plan and will be eligible for future equity awards according to the same program. Mr. Moore will enter into the company’s standard indemnification agreement for directors and executive officers.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Corvus Pharmaceuticals (CRVS) announce in this Form 8-K?

Corvus Pharmaceuticals announced that its Board of Directors appointed David Moore as a Class III director effective October 2, 2025, with a term expiring at the 2028 annual meeting of stockholders.

What board committees will David Moore serve on at Corvus Pharmaceuticals (CRVS)?

David Moore was appointed to the Compensation Committee and the Nominating and Corporate Governance Committee, effective October 2, 2025.

How will David Moore be compensated as a director of Corvus Pharmaceuticals (CRVS)?

Under the non-employee director compensation program, David Moore will receive a $35,000 annual cash retainer for Board service, plus $6,000 annually for serving on the Compensation Committee and $4,000 annually for serving on the Nominating Committee, all earned quarterly and prorated for the remainder of the current quarter.

What equity award will David Moore receive from Corvus Pharmaceuticals (CRVS)?

David Moore will receive an automatic initial stock option to purchase 30,000 shares of Corvus Pharmaceuticals common stock under the company’s 2016 Equity Incentive Award Plan and will be eligible for subsequent equity awards in line with the non-employee director compensation program.

What is the length of David Moore’s term on the Corvus Pharmaceuticals (CRVS) board?

David Moore was appointed as a Class III director with a term expiring at the 2028 annual meeting of stockholders and will serve until his successor is elected and qualified or until his earlier death, resignation, or removal.

Does David Moore receive any additional protections as a Corvus Pharmaceuticals (CRVS) director?

David Moore will enter into Corvus Pharmaceuticals’ standard indemnification agreement for directors and executive officers, which is the same form previously filed as an exhibit to the company’s Form 10-K.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/02/2025 - 04:37 PM EDT Learn about SEC filing dates

0001626971false00016269712025-10-022025-10-02

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 2, 2025

Corvus Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-37719		46-4670809
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

​

​ ​	​
901 Gateway Boulevard, Third Floor South San Francisco, CA		94080
(Address of principal executive offices)	​	(Zip Code)

​

Registrant’s telephone number, including area code: (650) 900-4520

Former name or former address, if changed since last report: Not applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​
Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, Par Value $0.0001 per share	CRVS	Nasdaq Global Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 2, 2025, the Board of Directors (the “Board”) of Corvus Pharmaceuticals, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee (the “Nominating Committee”), appointed David Moore to the Board. Mr. Moore was appointed as a Class III director with a term expiring at the 2028 annual meeting of stockholders and until his successor is elected and qualified, or until his earlier death, resignation or removal. Mr. Moore was also appointed to the Compensation Committee of the Board (the “Compensation Committee”) and the Nominating Committee, effective October 2, 2025.

Pursuant to the Company’s non-employee director compensation program, as a non-employee director, Mr. Moore will receive (i) a $35,000 annual retainer for his service on the Board, earned on a quarterly basis and prorated for the remainder of the current calendar quarter and (ii) an automatic initial grant of a stock option to purchase 30,000 shares of Common Stock under the Company’s 2016 Equity Incentive Award Plan. Mr. Moore will receive additional annual cash compensation of $6,000 for his service as a member of the Compensation Committee and an additional annual cash compensation of $4,000 for his service as a member of the Nominating Committee, both earned on a quarterly basis and prorated for the remainder of the current calendar quarter. Mr. Moore will also be eligible for subsequent equity awards in accordance with the Company’s non-employee director compensation program.

The foregoing description is qualified in its entirety by reference to the text of the Company’s non-employee director compensation program, the form of which was filed as Exhibit 10.12 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 25, 2025.

In addition, Mr. Moore will enter into the Company’s standard indemnification agreement for directors and executive officers, the form of which was filed as Exhibit 10.6 to the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2025.

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​		CORVUS PHARMACEUTICALS, INC.
​	​	​
Date: October 2, 2025	​	By:	/s/ Leiv Lea
​	​	​	Leiv Lea
​	​	​	Chief Financial Officer

​

​

​

​